Penserra Capital Management LLC Neurocrine Biosciences Inc Transaction History

Penserra Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $560,049 - $700,972	-5,280 Reduced 82.91%	1,088 $143,000
Q3 2023 Nov 15, 2023	BUY	$94.02 - $117.1 $598,719 - $745,692	6,368 New	6,368 $716,000
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $784,857 - $1.1 Million	-8,162 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $694,504 - $1.06 Million	8,162 New	8,162 $995,000
Q1 2019 May 08, 2019	SELL	$69.31 - $91.53 $84,280 - $111,300	-1,216 Closed	0 $0
Q4 2018 Feb 06, 2019	BUY	$68.32 - $124.36 $83,077 - $151,221	1,216 New	1,216 $86,000

627

94.3M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.